Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial-Reference-Cited by-同舟云学术

Investigating the Bioavailability and Insulin-like Growth Factor-I Release of Two Different Strengths of Somapacitan: A Randomised, Double-Blind Crossover Trial

Published:2024-07 Issue:7 Volume:63 Page:1015-1024
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Dombernowsky Sarah Louise^ORCID,Damholt Birgitte Bentz^ORCID,Højby Rasmussen Michael^ORCID,Sværke Claus^ORCID,Kildemoes Rasmus Juul^ORCID

Funder

Novo Nordisk A/S

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40262-024-01395-y.pdf

Reference37 articles.

1. Miller BS, Blair JC, Rasmussen MH, Maniatis A, Kildemoes RJ, Mori J, et al. Weekly somapacitan is effective and well tolerated in children with GH deficiency: the randomized phase 3 REAL4 trial. J Clin Endocrinol Metab. 2022;107:3378–88.

2. Juul A, Backeljauw P, Højby M, Kawai M, Kildemoes RJ, Linglart A, et al. Somapacitan in children born small for gestational age: a multi-centre, open-label, controlled phase 2 study. Eur J Endocrinol. 2023;188:lvac008.

3. Christiansen JS, Backeljauw PF, Bidlingmaier M, Biller BM, Boguszewski MC, Casanueva FF, et al. Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. Eur J Endocrinol. 2016;174:C1-8.

4. Yuen KCJ, Miller BS, Biller BMK. The current state of long-acting growth hormone preparations for growth hormone therapy. Curr Opin Endocrinol Diabetes Obes. 2018;25:267–73.

5. Haverkamp F, Johansson L, Dumas H, Langham S, Tauber M, Veimo D, et al. Observations of nonadherence to recombinant human growth hormone therapy in clinical practice. Clin Ther. 2008;30:307–16.